Fintel on MSN10h
Benchmark Initiates Coverage of Kamada (KMDA) with Buy Recommendation
Fintel reports that on March 21, 2025, Benchmark initiated coverage of Kamada (NasdaqGS:KMDA) with a Buy recommendation.
CNBCTV1814d
Biocon Biologics’ biosimilar Yesintek shows positive phase 3 results for psoriasis treatment
The findings, which confirm the biosimilar’s efficacy and safety profile compared to Stelara, are being presented at the 2025 ...
Business Insider19d
EQS-News: FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are ...
pharmaphorum1d
Fourth Humira biosimilar set for EU approval
EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
PMLiVE29d
EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases
A biosimilar, according to the European Medicines Agency (EMA), is a biological medicine that is highly similar to one already approved in the EU. This means patients can expect the same safety and ...
Biocon shares in focus after successful results of Yesintek in Phase 3
Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...
Business Wire19d
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi ® (ustekinumab-aauz)
Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are currently in ...
PharmiWeb25d
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are currently in ...
The Victoria Advocate15d
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
This milestone underscores our commitment to providing cost-effective, high-quality biosimilars to patients ... and European Medicines Agency (EMA). The safety profile of YESINTEK was similar ...